Braveheart Bio Shares One-Year Heart Drug Data, Plans New Fixed-Dose Trial

Impact · against what's priced in

BRVE shares are positioned for a significant catalyst in H1 2027 with the expected top-line results from Hengrui's Phase III study. Positive one-year extension data and a cash runway extending into 2029 reduce immediate clinical and financial risk, supporting the probability of success for upcoming Phase III trials.

BRVE+0.60

No priced-in read yet

In context

The company provided positive one-year data showing a 17.3 point symptom improvement and no serious adverse events, while confirming a cash runway into 2029 and a major binary catalyst in H1 2027 via Hengrui's Phase III results.

Read from the article alone

• biotech
• BRVE
• cardiovascular
• clinical trials
• drug development
• fda
• heart disease
• myosin inhibitor
• phase ii
• phase iii

Search tags